Evidence map›Paper›PMID 40895048›Full record

ArticlePeerJ2025

Longitudinal changes in estimated glomerular filtration rates in chronic hepatitis B patients treated with Tenofovir Alafenamide

Xuan Li, Qiang Wu, Fang Huang, Changxiang Lai, Fengjuan Chen, Juan Meng, Fang Wang, Hui Zeng, Lina Zhang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xuan Li *Department of Liver Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
Qiang Wu *Department of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
Fang HuangMedical Affairs Department, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
Changxiang LaiDepartment of Liver Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
Fengjuan ChenDepartment of Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
Juan MengDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
Fang WangDepartment of Liver Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
Hui ZengMedical Affairs Department, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
Lina ZhangDepartment of Liver Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: For individuals with chronic hepatitis B (CHB) at higher risk of nephrotoxicity, entecavir (ETV) and tenofovir alafenamide (TAF) are recommended antiviral options. This study aimed to investigate kidney safety among treatment-naïve individuals with CHB receiving TAF versus ETV. Method: Treatment-naïve individuals with CHB receiving either TAF or ETV from July 2019 to December 2020 were included. Follow-up data on estimated glomerular filtration rates (eGFR) were collected. Factors related to chronic kidney disease (CKD) development were analyzed by Cox regression analysis. Generalized additive mixed model (GAMM) was employed to investigate temporal eGFR changes and the association between the extent of follow-up eGFR change and antiviral agents. Results: 466 treatment-naïve individuals with CHB were included, with 296 in the ETV group and 170 in the TAF group. In the subgroup of individuals with a baseline eGFR higher than 90 mL/min/1.73 m Conclusion: The kidney safety profile of TAF among treatment-naïve individuals with CHB was comparable to that of ETV, without significant difference in developing CKD. Stratified analyses further revealed that TAF demonstrated superior kidney benefits compared to ETV specifically in males or patients aged over 35 years.

Indexed as

AdenineAntiviral AgentsGlomerular Filtration RateGuanineHepatitis B, ChronicRenal Insufficiency, ChronicTenofovirAdultAlanineFemaleHumansLongitudinal StudiesMaleMiddle AgedRetrospective StudiesAdenineAlanineAntiviral AgentsentecavirGuanineTenofovirtenofovir alafenamideEntecavirEstimated glomerular filtration ratesHepatitis B virusKidney safetyTenofovir alafenamide

Identifiers

PMID40895048
PMCPMC12396210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.